Nov 15, 2021 7:00am EST Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Use of TNX-1700, a Stabilized Recombinant Form of Trefoil Factor 2 (TFF2), for Treating Gastric and Pancreatic Cancers
Nov 9, 2021 7:00am EST Tonix Pharmaceuticals Presents Phase 1 Formulation Development Data for TNX-601 CR in a Poster Presentation at CNS Summit 2021
Nov 8, 2021 4:05pm EST Tonix Pharmaceuticals Presents Positive Results from Phase 3 RELIEF Study of TNX-102 SL for the Management of Fibromyalgia at the American College of Rheumatology Convergence 2021
Nov 8, 2021 7:00am EST Tonix Pharmaceuticals Reports Third Quarter 2021 Financial Results and Operational Highlights
Oct 15, 2021 7:00am EDT Tonix Pharmaceuticals Announces Ribbon-Cutting Ceremony for its Infectious Disease R&D Center in Maryland
Oct 7, 2021 7:00am EDT Tonix Pharmaceuticals to Participate in the A.G.P. Virtual Healthcare Conference
Oct 4, 2021 7:00am EDT Tonix Pharmaceuticals Announces Completion of Acquisition of Infectious Disease R&D Center in Frederick, Maryland
Sep 27, 2021 7:00am EDT Tonix Pharmaceuticals Announces Oral Presentation at the American College of Rheumatology Convergence 2021
